What is the current valuation of the Gene Therapy Market as of 2024?

The Gene Therapy Market was valued at 6.12 USD Billion in 2024. Read More

What is the projected market size for the Gene Therapy Market by 2035?

The market is projected to reach 41.63 USD Billion by 2035. Read More

What is the expected CAGR for the Gene Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Gene Therapy Market during 2025 - 2035 is 19.04%. Read More

Which companies are considered key players in the Gene Therapy Market?

Key players include Novartis, Gilead Sciences, Spark Therapeutics, and Bluebird Bio, among others. Read More

What are the main segments of the Gene Therapy Market based on vector type?

The main segments based on vector type are Viral Vector, valued at 25.0 USD Billion, and Non-Viral Vector, valued at 16.63 USD Billion. Read More

How do the different gene types perform in the Gene Therapy Market?

In 2024, Antigen and Tumor Suppressor gene types were valued at 5.5 USD Billion and 6.2 USD Billion, respectively. Read More

What applications dominate the Gene Therapy Market?

Oncological Disorders and Rare Diseases are leading applications, valued at 5.92 USD Billion and 8.12 USD Billion in 2024. Read More

What delivery methods are utilized in the Gene Therapy Market?

The market segments include In Vivo Gene Therapy, projected to reach 25.09 USD Billion, and Ex Vivo Gene Therapy, expected to reach 16.54 USD Billion. Read More

What is the potential growth of the Gene Therapy Market in the coming years?

The Gene Therapy Market appears poised for substantial growth, with projections indicating a significant increase by 2035. Read More

How does the Gene Therapy Market compare to other biopharmaceutical sectors?

The Gene Therapy Market, with its projected growth, suggests a robust position compared to other biopharmaceutical sectors, particularly in innovative treatments. Read More

Gene Therapy Market

ID: MRFR/Pharma/6927-CR

167 Pages

Nidhi Mandole

Last Updated: April 02, 2026

Gene Therapy Market Research Report: Size, Share, Trend Analysis By Vector Type (Viral Vector (Lentiviral Vectors (LVVs), Retrovirus Vectors, Adenoviral Vectors (AdVs), Adeno-associated Viral Vectors (AAVs) and Non-Viral Vector (Physical Vector, Chemical Vector), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), By Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others), by Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy) and Region (North America, Europe, Asia-Pacific, Rest of the World)) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Vector Type (USD Billion)
  1. 4.1.1 Viral Vector
  2. 4.1.2 Non-Viral Vector
2. 4.2 Healthcare, BY Gene Type (USD Billion)
  1. 4.2.1 Antigen
  2. 4.2.2 Cytokine
  3. 4.2.3 Tumor Suppressor
  4. 4.2.4 Suicide
  5. 4.2.5 Deficiency
  6. 4.2.6 Growth Factors
  7. 4.2.7 Receptors
  8. 4.2.8 Others
3. 4.3 Healthcare, BY Application (USD Billion)
  1. 4.3.1 Oncological Disorders
  2. 4.3.2 Rare Diseases
  3. 4.3.3 Cardiovascular Diseases
  4. 4.3.4 Neurological Disorders
  5. 4.3.5 Infectious Diseases
  6. 4.3.6 Others
4. 4.4 Healthcare, BY Delivery Method (USD Billion)
  1. 4.4.1 In Vivo Gene Therapy
  2. 4.4.2 Ex Vivo Gene Therapy
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Spark Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bluebird Bio (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sangamo Therapeutics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 CRISPR Therapeutics (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY VECTOR TYPE
4. 6.4 US MARKET ANALYSIS BY GENE TYPE
5. 6.5 US MARKET ANALYSIS BY APPLICATION
6. 6.6 US MARKET ANALYSIS BY DELIVERY METHOD
7. 6.7 CANADA MARKET ANALYSIS BY VECTOR TYPE
8. 6.8 CANADA MARKET ANALYSIS BY GENE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY APPLICATION
10. 6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY VECTOR TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY GENE TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
15. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD
16. 6.16 UK MARKET ANALYSIS BY VECTOR TYPE
17. 6.17 UK MARKET ANALYSIS BY GENE TYPE
18. 6.18 UK MARKET ANALYSIS BY APPLICATION
19. 6.19 UK MARKET ANALYSIS BY DELIVERY METHOD
20. 6.20 FRANCE MARKET ANALYSIS BY VECTOR TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY GENE TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION
23. 6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD
24. 6.24 RUSSIA MARKET ANALYSIS BY VECTOR TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY GENE TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION
27. 6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD
28. 6.28 ITALY MARKET ANALYSIS BY VECTOR TYPE
29. 6.29 ITALY MARKET ANALYSIS BY GENE TYPE
30. 6.30 ITALY MARKET ANALYSIS BY APPLICATION
31. 6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD
32. 6.32 SPAIN MARKET ANALYSIS BY VECTOR TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY GENE TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION
35. 6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY VECTOR TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY GENE TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY VECTOR TYPE
42. 6.42 CHINA MARKET ANALYSIS BY GENE TYPE
43. 6.43 CHINA MARKET ANALYSIS BY APPLICATION
44. 6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD
45. 6.45 INDIA MARKET ANALYSIS BY VECTOR TYPE
46. 6.46 INDIA MARKET ANALYSIS BY GENE TYPE
47. 6.47 INDIA MARKET ANALYSIS BY APPLICATION
48. 6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD
49. 6.49 JAPAN MARKET ANALYSIS BY VECTOR TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY GENE TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION
52. 6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY VECTOR TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY GENE TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD
57. 6.57 MALAYSIA MARKET ANALYSIS BY VECTOR TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY GENE TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD
61. 6.61 THAILAND MARKET ANALYSIS BY VECTOR TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY GENE TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION
64. 6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD
65. 6.65 INDONESIA MARKET ANALYSIS BY VECTOR TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY GENE TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION
68. 6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD
69. 6.69 REST OF APAC MARKET ANALYSIS BY VECTOR TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY GENE TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY VECTOR TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY GENE TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION
77. 6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD
78. 6.78 MEXICO MARKET ANALYSIS BY VECTOR TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY GENE TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION
81. 6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD
82. 6.82 ARGENTINA MARKET ANALYSIS BY VECTOR TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY GENE TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENE TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY VECTOR TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY GENE TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY VECTOR TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY GENE TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD
99. 6.99 REST OF MEA MARKET ANALYSIS BY VECTOR TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY GENE TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY VECTOR TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY VECTOR TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY GENE TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY GENE TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY VECTOR TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Vector Type (USD Billion, 2025-2035)

Viral Vector
Non-Viral Vector

Healthcare By Gene Type (USD Billion, 2025-2035)

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth Factors
Receptors
Others

Healthcare By Application (USD Billion, 2025-2035)

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Others

Healthcare By Delivery Method (USD Billion, 2025-2035)

In Vivo Gene Therapy
Ex Vivo Gene Therapy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”